Healthcare / Medical Instruments & SuppliesWarsaw
$55.20
+0.20 (+0.36%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 34% · confianza 18%
FCF escenarios
weak_data · normalized FCF $-39.2M · quality 51.3/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
50/100
C
Piotroski
4/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
12/100
SEC 0%
Sin guardar todavía.
Market Cap
$505M
P/E
5.3x
↓EV/EBITDA
16.6x
↑ROE
-2.3%
↓Gross Margin
16.9%
↓Debt/Equity
0.01
↓TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2021–2023 · 2 años de histórico normalizado
Revenue CAGR
-47.9%
FCF CAGR
—
FCF margin
-8.3%
FCF / Net income
1.99x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $469.1M · net income $-19.7M · FCF $-39.2M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2023 | 2022 | 2021 |
|---|---|---|---|---|
| Income Statement | ||||
| Revenue | $469.1M | $469.1M | $542.5M | $1.73B |
| Net Income | $-19.7M | $-19.7M | $-189.6M | $446.9M |
| EBITDA | $19.2M | $19.2M | $-160.2M | $496.6M |
| EPS | -2.05 | -2.05 | -19.41 | 44.15 |
| Gross Margin | 16.9% | 16.9% | 16.3% | 39.6% |
| Operating Margin | -20.1% | -20.1% | -13.5% | 29.8% |
| Net Margin | -4.2% | -4.2% | -35.0% | 25.9% |
| Balance Sheet | ||||
| Debt/Equity | 0.01 | 0.01 | 0.00 | 0.00 |
| Current Ratio | 6.95 | 6.95 | — | — |
| Cash Flow | ||||
| Free Cash Flow | $-39.2M | $-39.2M | $-68.9M | $326.3M |
| Returns | ||||
| ROE | -2.3% | -2.3% | -18.8% | 39.1% |
| Valuation | ||||
| P/E | 5.28 | 5.28 | — | 2.31 |
| EV/EBITDA | 16.55 | 16.55 | — | 1.41 |
| P/B | 0.61 | 0.61 | 0.48 | 0.90 |
| Growth & Yield | ||||
| Revenue Growth | -13.5% | -13.5% | -68.6% | — |
| EPS Growth | 89.4% | 89.4% | -144.0% | — |
| Dividend Yield | 1.2% | 1.2% | — | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
+22.0%
Start / end P/E
n/dx → n/dx
EPS bridge
-19.41 → -2.05
Residual
+20.8%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.